BioLife Solutions Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de BioLife Solutions de 60.7% y 12.4% por año respectivamente. Se prevé que el BPA crezca en un 61.3% al año. Se espera que la rentabilidad financiera sea de -2.1% en 3 años.

Información clave

62.1%

Tasa de crecimiento de los beneficios

62.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	16.5%
Tasa de crecimiento de los ingresos	13.3%
Rentabilidad financiera futura	-2.1%
Cobertura de analistas	Good
Última actualización	25 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Mar 12

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

Feb 19

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Dec 19

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Aug 17

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Dec 10

BioLife: What The Future Holds

Oct 19

BioLife Solutions COO Roderick de Greef to retire

Oct 03

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Sep 27

BioLife Solutions GAAP EPS of -$1.71 misses by $1.50, revenue of $40.5M beats by $1.33M

Aug 09

BioLife Solutions: Sell-Side Posture Overly Optimistic, Rate Neutral

Jul 29

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Jun 15

BioLife: Can This Company Successfully Turn Around?

Apr 18

Temporary Setbacks At BioLife

Mar 02

Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?

Jan 11

BioLife: Poised For Growth

Dec 22

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:BLFS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	159	7	9	22	3
12/31/2025	119	-22	-15	9	6
12/31/2024	101	-48	-33	2	8
12/31/2023	143	-66	-24	-12	N/A
9/30/2023	155	-102	-22	-7	N/A
6/30/2023	162	-83	-17	-1	N/A
3/31/2023	163	-146	-19	-3	N/A
12/31/2022	162	-140	-22	-8	N/A
9/30/2022	155	-106	-28	-17	N/A
6/30/2022	148	-96	-27	-17	N/A
3/31/2022	139	-15	-27	-14	N/A
12/31/2021	119	-9	-19	-5	N/A
9/30/2021	97	5	-19	-2	N/A
6/30/2021	74	4	-19	-4	N/A
3/31/2021	53	-20	-3	8	N/A
12/31/2020	48	2	-1	7	N/A
9/30/2020	42	7	0	3	N/A
6/30/2020	37	16	1	5	N/A
3/31/2020	34	39	-3	1	N/A
12/31/2019	27	-2	-1	1	N/A
9/30/2019	25	-32	2	3	N/A
6/30/2019	23	-39	2	2	N/A
3/31/2019	22	-44	2	3	N/A
12/31/2018	20	-25	2	2	N/A
9/30/2018	17	1	2	3	N/A
6/30/2018	15	0	2	2	N/A
3/31/2018	12	-2	1	1	N/A
12/31/2017	11	-3	0	1	N/A
9/30/2017	10	-5	N/A	-1	N/A
6/30/2017	9	-6	N/A	-2	N/A
3/31/2017	9	-7	N/A	-3	N/A
12/31/2016	8	-7	N/A	-4	N/A
9/30/2016	8	-5	N/A	-5	N/A
6/30/2016	7	-5	N/A	-5	N/A
3/31/2016	7	-4	N/A	-5	N/A
12/31/2015	6	-4	N/A	-5	N/A
9/30/2015	6	-4	N/A	-4	N/A
6/30/2015	6	-4	N/A	-4	N/A
3/31/2015	6	-4	N/A	-4	N/A
12/31/2014	6	-3	N/A	-3	N/A
9/30/2014	7	-3	N/A	-2	N/A
6/30/2014	8	-2	N/A	-2	N/A
3/31/2014	9	-2	N/A	-1	N/A
12/31/2013	9	-1	N/A	0	N/A
9/30/2013	9	-1	N/A	0	N/A
6/30/2013	8	-1	N/A	0	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BLFS sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que BLFS sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que BLFS sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (12.4% al año) de BLFS crezcan más rápidamente que los del mercado US (7.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12.4% al año) de BLFS crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: BLFS se prevé que no sea rentable en 3 años.

BioLife Solutions Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast breakeven date pushed back to 2026

Forecast breakeven date pushed back to 2026

Consensus EPS estimates fall by 75%

Consensus revenue estimates decrease by 18%, EPS upgraded

Biolife Solutions, Inc. Provides Earnings Guidance for the Year 2023

Price target decreased by 17% to US$25.14

Recent updates

BioLife Solutions, Inc. to Report Q1, 2024 Results on May 09, 2024

Forecast breakeven date pushed back to 2026

An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $2.6 million.

An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS).

Lead Director notifies of intention to sell stock

Lead Director recently sold US$190k worth of stock

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Full year 2023 earnings: EPS exceeds analyst expectations

Forecast breakeven date pushed back to 2026

BioLife Solutions, Inc. to Report Q4, 2023 Results on Feb 29, 2024

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Consensus EPS estimates fall by 75%

Third quarter 2023 earnings: EPS misses analyst expectations

BioLife Solutions, Inc. to Report Q3, 2023 Results on Nov 09, 2023

BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Consensus revenue estimates decrease by 18%, EPS upgraded

Biolife Solutions, Inc. Provides Earnings Guidance for the Year 2023

Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Price target decreased by 17% to US$25.14

BioLife Solutions, Inc. to Report Q2, 2023 Results on Aug 08, 2023

BioLife Solutions, Inc., Annual General Meeting, Jul 21, 2023

BioLife Solutions, Inc. announced delayed 10-Q filing

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Biolife Solutions, Inc. Reaffirms Earnings Guidance for the Fiscal 2023

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Chairman of Scientific Advisory Board exercised options and sold US$346k worth of stock

Chairman & CEO recently sold US$64k worth of stock

Chairman of Scientific Advisory Board exercised options and sold US$391k worth of stock

Consensus EPS estimates fall by 62%

Full year 2022 earnings: EPS misses analyst expectations

Chairman & CEO recently sold US$98k worth of stock

Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Chairman of Scientific Advisory Board exercised options and sold US$436k worth of stock

Director recently sold US$88k worth of stock

Director recently sold US$88k worth of stock

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Chairman of Scientific Advisory Board exercised options and sold US$321k worth of stock

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Now 20% undervalued after recent price drop

Price target decreased to US$31.50

President & COO recently sold US$477k worth of stock

Price target decreased to US$31.50

BioLife Solutions, Inc. Updates Revenue Guidance of 2022

BioLife Solutions, Inc. to Report Q3, 2022 Results on Nov 09, 2022

BioLife: What The Future Holds

President & COO recently sold US$194k worth of stock

BioLife Solutions, Inc. Announces Executive Changes

BioLife Solutions COO Roderick de Greef to retire

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors

Biolife Solutions Appoints Cell Therapy Executive Timothy L. Moore to Its Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

BioLife Solutions, Inc. Provides Revenue Guidance for the Year 2022

BioLife Solutions GAAP EPS of -$1.71 misses by $1.50, revenue of $40.5M beats by $1.33M

BioLife Solutions, Inc. to Report Q2, 2022 Results on Aug 09, 2022

BioLife Solutions: Sell-Side Posture Overly Optimistic, Rate Neutral

President & COO recently sold US$145k worth of stock

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

BioLife Solutions, Inc. Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services

Price target decreased to US$37.13

Biolife Solutions, Inc. Affirms Revenue Guidance for the Year 2022

BioLife Solutions, Inc. to Report Q1, 2022 Results on May 09, 2022

BioLife Solutions, Inc., Annual General Meeting, Jun 09, 2022

BioLife: Can This Company Successfully Turn Around?

BioLife Solutions, Inc. announced delayed annual 10-K filing

Price target decreased to US$56.86